Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07672431 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression

StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The goal of this clinical trial is to learn if adding the TheraBionic P1 device to standard of care third line treatment for adult women with metastatic triple negative breast cancer (mTNBC) who have failed, not tolerated, or progressed on standard first- and second-line treatment options can work better than the standard of care alone. The main questions it aims to answer is: * will the addition of the TheraBionic P1 device to standard of care third line treatment affect progression free and overall survival in these participants
Trial Details
NCT Number NCT07672431
Lead Sponsor Barbara Ann Karmanos Cancer Institute
Collaborators: THERABIONIC INC., Ucancervive
Conditions
(from sponsor)		 Triple Negative Breast Cancer
Related terms Triple Negative Breast Neoplasms
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov